TABLE IV.
Monoclonal antibody (MAb) eligibility
| Eligibility factors | Trastuzumab Breast | Bevacizumab | ||
|---|---|---|---|---|
| Adjuvant | Palliative | nsclc Palliative | Colorectal Palliative | |
| Treated with chemotherapy (%) | 4024,27 | 7017 | 3223,24,28,29 | 5019,25,30 |
| With treatment indication (%)a | 23b,31 | 23b,31 | 60c,32–34 | 100 |
| Excluded (%) d | 5 | 5 | 5 | 5 |
| Total eligible (%) | 9 | 15 | 18 | 48 |
a
her2/neu-positive breast cancer, all nsclc excluding squamous histology, and all colorectal cancers.
b
her2/neu-positive breast cancer.
c
All nsclc, excluding squamous cell histology.
d
Assumption secondary to possible cardiac causes or high bleeding risks (see Table II).
nsclc = non-small-cell lung cancer.